YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

(2019) Georgina V Long et al.   LANCET ONCOLOGY

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity

(2018) Sabine Hoves et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases

(2018) Pooja Dhupkar et al.   Cancer Medicine

Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906)

(2018) Wing Lam et al.   Frontiers in Pharmacology

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a Pro-inflammatory Microenvironment in the Lymph Node

(2017) Lifang Cheng et al.   MOLECULAR THERAPY

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies

(2017) Géraldine Genard et al.   Frontiers in Immunology

Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan

(2016) W Chen et al.   Cell Death & Disease

Autophagy-induced RelB/p52 activation mediates tumour-associated macrophage repolarisation and suppression of hepatocellular carcinoma by natural compound baicalin

(2015) H-Y Tan et al.   Cell Death & Disease

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner

(2015) Rikke B. Holmgaard et al.   Cell Reports

The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018)

(2015) Wing Lam et al.   BMC Complementary and Alternative Medicine

PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment

(2015) Wing Lam et al.   Scientific Reports

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

(2014) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

Macrophage Regulation of Tumor Responses to Anticancer Therapies

(2013) Michele De Palma et al.   CANCER CELL

First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer

(2013) Muhammad Wasif Saif et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

(2013) Andrew M. Intlekofer et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Natural inhibitors of indoleamine 3,5-dioxygenase induced by interferon-gamma in human neural stem cells

(2012) S. Chen et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Preclinical studies of the Chinese Herbal Medicine formulation PHY906 (KD018) as a potential adjunct to radiation therapy

(2012) Sara Rockwell et al.   INTERNATIONAL JOURNAL OF RADIATION BIOLOGY

Old formula, new Rx: The journey of PHY906 as cancer adjuvant therapy

(2012) Shwu-Huey Liu et al.   JOURNAL OF ETHNOPHARMACOLOGY

Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment

(2011) Ena Wang et al.   BMC Medical Genomics

The development and functions of CD4+ T cells expressing a transgenic TCR specific for an MHC-I-restricted tumor antigenic epitope

(2011) Xue Han et al.   Cellular & Molecular Immunology

A Phase I Study of the Chinese Herbal Medicine PHY906 as a Modulator of Irinotecan-based Chemotherapy in Patients with Advanced Colorectal Cancer

(2011) Shivaani Kummar et al.   Clinical Colorectal Cancer

Hepatocellular Carcinoma

(2011) Hashem B. El-Serag   NEW ENGLAND JOURNAL OF MEDICINE

Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS)

(2010) Wei Zhang et al.   JOURNAL OF CHROMATOGRAPHY A

Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies

(2010) M. Wasif Saif et al.   PHYTOMEDICINE

The Four-Herb Chinese Medicine PHY906 Reduces Chemotherapy-Induced Gastrointestinal Toxicity

(2010) W. Lam et al.   Science Translational Medicine

A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqi Tang (HQT) and PHY906

(2010) Robert Tilton et al.   Chinese Medicine

Molecular targeted therapies in hepatocellular carcinoma

(2008) Josep M. Llovet et al.   HEPATOLOGY